Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac Tetanus Vaccine in Adults
NCT06049940Phase 3Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tetanus toxoid in Tetanus, sponsored by Sinovac Life Sciences. Started Sep 2023; status: completed.
02
Drugs
tetanus toxoid
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06049940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049940.